NY-CPV
2.4.2024 15:01:33 CEST | Business Wire | Press release
Cohen Private Ventures (CPV), the family office of Steven A. Cohen, is proud to officially unveil New York Golf Club (NYGC) and its four-player roster of PGA TOUR stars featuring Rickie Fowler, Xander Schauffele, Matt Fitzpatrick and New York-native Cameron Young ahead of the inaugural 2025 TGL presented by SoFi season.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402326760/en/
New York Golf Club team roster: Cameron Young, Matt Fitzpatrick, Xander Schauffele, Rickie Fowler (Photo: Business Wire)
New York is synonymous with world class, and its golf scene is no exception. Steeped in the history of the sport, with some of the greatest and most iconic courses in the world, NYGC is ready to build upon its rich legacy of golf and redefine what it means to be a golf club representing a city known for its constant reinvention. NYGC is excited to represent the tri-state area in this innovative and accessible version of the sport.
“New Yorkers expect and deserve the best, and we couldn’t be more excited to have four of the best players in the world serve as an extension of the thriving golf and sporting culture of our city and region,” said Steve Cohen, owner of the NYGC and the New York Mets. “Rickie, Xander, Matt, and Cameron’s unwavering dedication to the sport, successful track records, and passion for winning is undisputable, and we look forward to watching them compete on golf’s newest stage.”
TEAM NAME & LOGO
New York City is the greatest city in the world, and NYGC embraces the privilege and responsibility that comes with representing the five boroughs and surrounding communities. NYGC will build upon our world-class golfing and sports heritage to deliver a team New York fans can be proud of.
NYGC’s logo is inspired by New York’s state bird, the Eastern Bluebird. These birds are commonly found where forests meet fields, and particularly on golf courses. Our design features a dynamic swinging club crafted into the form of a wing with four grooves, one for each of our players. The circle pays homage to the circles on our scorecards and the iconic NYC Subway circle.
MEET THE PLAYERS
Fowler is one of the most popular players on the PGA TOUR. Since turning professional in 2009, he has recorded 10 professional wins, including the 2015 PLAYERS Championship. His most recent title came at the 2023 Rocket Mortgage Classic in July. Fowler brings a wealth of team golf experience as a veteran of five U.S. Ryder Cup teams, three U.S. Presidents Cup teams, one World Cup, Walker Cup and Palmer Cup teams from his time as an amateur player. He also represented the U.S. in the 2016 Olympic Games.
“I am thrilled to be joining New York Golf Club for the inaugural TGL season,” said Fowler. “It is an incredible opportunity to represent one of the greatest cities in the world, and I look forward to competing in 2025.”
Schauffele, currently No. 5 in the Official World Golf Ranking, has been a top-10 player in the world for the better part of the last five years and regularly placing in the Top 10 of major championships. Since turning professional in 2015, he has recorded seven PGA TOUR titles, two DP World Tour wins and an Olympic Gold Medal in Tokyo. He was named the PGA TOUR Rookie of the Year in 2016-2017 and represented the U.S. in two Presidents Cup teams and two Ryder Cup teams.
“I’ve built my career on a foundation of hard work, grit, and determination, which couldn’t better reflect the people of New York City,” said Schauffele. “It’s a true honor to both grow the game and represent this incredible city.”
Fitzpatrick became England’s first major champion since 2016 when he won the 2022 U.S. Open at The Country Club in Brookline, Massachusetts, joining Jack Nicklaus as the only players to have won a U.S. Open and U.S. Amateur at the same venue. Since turning professional in 2014, Fitzpatrick has recorded two PGA TOUR titles and eight international victories, and represented England on three European Ryder Cup teams. His most recent PGA TOUR victory came at the RBC Heritage in April 2023.
“Working with the team at Cohen Private Ventures on the launch of New York Golf Club has been an incredible experience,” said Fitzpatrick. “New York is one of the greatest cities in the world, and I could not be more excited to continue to deepen my connections there.”
The New York-native Young is quickly becoming a fan favorite on the PGA TOUR. In 2022, Young earned Rookie of the Year honors when he became the seventh player since 1980 to collect five runner-up finishes in a season, including a second-place finish at The Open Championship and tying for third at the PGA Championship. He made his debut on the Presidents Cup team in 2022. Cameron’s father David Young, recently retired after over 20 years as Sleepy Hollow Country Club’s Head Golf Professional.
“Having grown up a New Yorker, first learning to play at Sleepy Hollow, the opportunity to represent New York Golf Club feels surreal,” said Young. “Alongside Rickie, Xander, and Matt, I am confident we are going to be a highly competitive team in the upcoming TGL season.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402326760/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom